286 related articles for article (PubMed ID: 25909366)
1. Certolizumab pegol - A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn's disease.
Hurabielle C; Schneider P; Baudry C; Bagot M; Allez M; Viguier M
J Dermatolog Treat; 2016; 27(1):67-9. PubMed ID: 25909366
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn's disease: A case report.
Pender TM; Ayandibu G; Van Voorhees AS
Dermatol Ther; 2020 Nov; 33(6):e14352. PubMed ID: 32981217
[No Abstract] [Full Text] [Related]
3. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
5. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease.
Ferkolj I; Hocevar A; Golouh R; Dolenc Voljc M
Acta Dermatovenerol Alp Pannonica Adriat; 2006 Dec; 15(4):173-7. PubMed ID: 17982610
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
Sapienza MS; Cohen S; Dimarino AJ
Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
11. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient.
Wang N; Yu C; Wang W; Yang Q
J Dermatolog Treat; 2023 Dec; 34(1):2276044. PubMed ID: 37905433
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
15. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
Lee SD; Rubin DT; Sandborn WJ; Randall C; Younes Z; Schreiber S; Schwartz DA; Burakoff R; Binion D; Dassopoulos T; Arsenescu R; Gutierrez A; Scherl E; Kayhan C; Hasan I; Kosutic G; Spearman M; Sen D; Coarse J; Hanauer S
Inflamm Bowel Dis; 2016 Aug; 22(8):1870-80. PubMed ID: 27400222
[TBL] [Abstract][Full Text] [Related]
16. Substitution with Alternative Anti-TNFα Therapy (SAVANT)-Outcomes of a Crohn's Disease Cohort Undergoing Substitution Therapy with Certolizumab.
Boktor M; Motlis A; Aravantagi A; Sheth A; Jordan P; Morris J; Manas K; Hussain N; Cvek U; Trutschl M; Becker F; Alexander JS
Inflamm Bowel Dis; 2016 Jun; 22(6):1353-61. PubMed ID: 27104819
[TBL] [Abstract][Full Text] [Related]
17. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
Schreiber S
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
[TBL] [Abstract][Full Text] [Related]
18. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
[TBL] [Abstract][Full Text] [Related]
19. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
